Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | NCF1 | P14598 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31599195 | 1.00 | LOXL2 (0.67) | LOXL2KDM4ELMNAMAPTTP53 | |
| Bromide SCHEMBL9399386 | 0.98 | LOXL2 (0.64) | LOXL2KDM4ELMNAMAPTTP53 | |
| SCHEMBL10311166 | 0.85 | LOXL2 (0.60) | LOXL2KDM4ELMNAMAPTTP53 | |
| SCHEMBL6176955 | 0.85 | LOXL2 (0.60) | LOXL2KDM4ELMNAMAPTTP53 | |
| SCHEMBL3136413 | 0.84 | KDM4E (0.56) | LOXL2KDM4ELMNAMAPTTP53 | |
| SCHEMBL7358307 | 0.82 | LOXL2 (0.56) | LOXL2KDM4ELMNAMAPTTP53 | |
| SCHEMBL6112363 | 0.80 | LOXL2 (0.64) | LOXL2KDM4ELMNAMAPTTP53 | |
| SCHEMBL13067165 | 0.80 | LOXL2 (0.64) | LOXL2KDM4ELMNAMAPTTP53 | |
| SCHEMBL3972788 | 0.80 | LOXL2 (0.64) | LOXL2KDM4ELMNAMAPTTP53 | |
| SCHEMBL17266358 | 0.80 | LOXL2 (0.64) | LOXL2KDM4ELMNAMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 400 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-119432383-A | High-selectivity etching solution for radio frequency chip material | 湖北兴福电子材料股份有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-113979955-B | Preparation method of heterocyclic ester compound | 河南农业大学 | 2024-05-14 | — | — | CN | claimed |
| CN-114213307-A | Preparation method of N-alkyl substituted pyrrolidone compound | 河南农业大学 | 2022-03-22 | — | — | CN | claimed |
| CN-113979955-A | Preparation method of heterocyclic ester compound | 河南农业大学 | 2022-01-28 | — | — | CN | claimed |
| CN-112939857-A | Synthetic method of alkylated quinoline compound | 中国科学院大连化学物理研究所 | 2021-06-11 | — | — | CN | claimed |
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-11-17 | — | — | US | claimed |
| US-20180177776-A1 | COMPOSITIONS FOR THE TREATMENT OF CANCER AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED (US) | 2018-06-28 | — | — | US | claimed |
| WO-2016209688-A1 | COMPOSITIONS FOR THE TREATMENT OF CANCER AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2016-12-29 | — | — | WO | claimed |
| US-20120264810-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR UPTAKE AND INTRACELLULAR DELIVERY OF LIPID PARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-10-18 | — | — | US | claimed |
| WO-2011036557-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR UPTAKE AND INTRACELLULAR DELIVERY OF LIPID PARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-03-31 | — | — | WO | claimed |
| US-6620823-B2 | Antiinflammatory agents; rheumatic disorders | BRISTOL-MYERS SQUIBB PHARME COMPANY | 2003-09-16 | — | — | US | claimed |
| EP-1335907-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2003-08-20 | — | — | EP | claimed |
| US-6593330-B2 | Central nervous system disorders; antiserotonine agents | BIOVITRUM (SE) | 2003-07-15 | — | — | US | claimed |
| US-20020147200-A1 | Novel compounds and their use | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-10-10 | — | — | US | claimed |
| WO-2002040456-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2002-05-23 | — | — | WO | claimed |
| US-12459921-B2 | Isoindoline compound, preparation method, pharmaceutical composition and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-11-04 | — | — | US | disclosed |
| US-12435078-B2 | Pyridazinones and methods of use thereof | GFB (ABC), LLC (US) | 2025-10-07 | — | — | US | disclosed |
| EP-0133244-A2 | Phenylquinolinecarboxylic acids and derivatives as antitumor agents | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-02-20 | — | — | EP | disclosed |
| US-4429130-A | Pyrid-2'-yl-2-trifluoromethyl quinol-4-ylmethanes | BASF AKTIENGESELLSCHAFT (DE) | 1984-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | PIK3CA, MTOR, PIK3CD | LOXL2 4731/4885KDM4E 770/4885LMNA 4327/4885 |
| US-12459921-B2 | Isoindoline compound, preparation method, pharmaceutical composition and use thereof | CUL4B, CUL4A, UBQLN1 | LOXL2 2913/4885KDM4E 438/4885LMNA 1936/4885 |
| US-12435078-B2 | Pyridazinones and methods of use thereof | PDXK, ATP6V1B1, REN | LOXL2 1797/4885KDM4E 3899/4885LMNA 715/4885 |
| US-20020147200-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | LOXL2 1146/4885KDM4E 1971/4885LMNA 3306/4885 |
| US-20120264810-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR UPTAKE AND INTRACELLULAR DELIVERY OF LIPID PARTICLES | NPC1L1, ABCB4, NPC1 | LOXL2 3008/4885KDM4E 3424/4885LMNA 398/4885 |
| US-20180177776-A1 | COMPOSITIONS FOR THE TREATMENT OF CANCER AND USES THEREOF | PIK3CA, MTOR, PIK3CD | LOXL2 4692/4885KDM4E 535/4885LMNA 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.